Wall Street analyst estimates for Equillium, Inc. (EQ): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.05 | ||
| 2026-08-13 | $-0.04 | $-0.05 | +25.9% |
| 2026-05-13 | $-0.06 | $-0.04 | -50.0% |
| 2026-03-25 | $-0.04 | $-0.07 | +42.9% |
| 2025-11-13 | $-0.06 | $-0.14 | +57.1% |
| 2025-08-14 | $-0.16 | $-0.14 | -14.3% |
| 2025-05-14 | $-0.24 | $-0.23 | -4.3% |
| 2025-03-27 | $-0.16 | $-0.22 | +27.3% |
Valuation Ratios
| Price / Book | 3.70 |
| EV / EBITDA | -5.22 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $15.8M | $36.1M | $41.1M | 0 |
| Cost of Revenue | $122 | $6102 | $23000 | $45000 | 0 | 0 | 0 | 0 | $116000 |
| Gross Profit | -$122 | -$6102 | -$23000 | -$45000 | 0 | $15.8M | $36.1M | $41.1M | -$116000 |
| Research & Development | $1.3M | $4.9M | $17.6M | $19.4M | $26.4M | $37.5M | $37.0M | $37.4M | $12.8M |
| Selling, General & Admin | $378206 | $3.7M | $9.1M | $10.1M | $11.4M | $17.2M | $13.6M | $11.9M | $10.8M |
| Operating Expenses | $1.7M | $8.6M | $26.7M | $29.5M | $37.8M | $77.8M | $50.6M | $49.4M | $23.6M |
| Operating Income | -$1.7M | -$8.6M | -$26.7M | -$29.5M | -$37.8M | -$62.1M | -$14.5M | -$8.3M | -$23.6M |
| EBITDA | -$1.9M | -$10.7M | -$25.3M | -$28.7M | -$37.9M | -$61.3M | -$12.1M | -$7.6M | -$22.3M |
| Interest Expense | $379385 | $2.6M | $279000 | $1.1M | $1.1M | $1.1M | $491000 | 0 | 0 |
| Pre-tax Income | -$2.3M | -$13.2M | -$25.6M | -$29.8M | -$39.1M | -$62.4M | -$12.8M | -$7.7M | -$22.4M |
| Income Tax | -$2 | $140512 | 0 | 0 | 0 | 0 | $580000 | $361000 | 0 |
| Net Income | -$2.3M | -$13.2M | -$25.6M | -$29.8M | -$39.0M | -$62.4M | -$13.3M | -$8.1M | -$22.4M |
| EPS | $-0.13 | $-1.09 | $-1.47 | $-1.46 | $-1.35 | $-3.19 | $-0.38 | $-0.23 | $-0.39 |
| EPS (Diluted) | $-0.19 | $-1.09 | $-1.47 | $-1.46 | $-1.35 | $-3.19 | $-0.38 | $-0.23 | $-0.39 |
| Shares Outstanding (Diluted) | $11.7M | $12.2M | $17.4M | $20.4M | $28.8M | $33.7M | $34.7M | $35.4M | $91.9M |
Price
| Price | $1.85 |
| Market Cap | $117M |
| Exchange | NASDAQ |
| Country | US |
Related companies: COEP · CUE · FBIO · IPSC · MDCX · NRXP · OSTX
Explore sector: Healthcare · Biotechnology
More sections of EQ: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks